BridgeMD
New treatment option for Stroke
Official title Influence of Cerebral Oedema in Intracerebral Haemorrhage
ClinicalTrials.gov ID: NCT04621357
What this study is testing
What is Biological biomarkers?
Biological biomarkers is an investigational medicine, being studied as a potential treatment for stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- With a spontaneous ICH, i.e. non traumatic
- Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
- Patient insured under the French social security
- Consent form signed
You likely can't join if
- Pure intraventricular haemorrhages
- "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic...
- Pre-admission modified Rankin score of 4 or 5
- Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
- Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)
- Adults who are deprived of their liberty by judicial or administrative decision
See the full eligibility criteria
- With a spontaneous ICH, i.e. non traumatic
- Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
- Patient insured under the French social security
- Consent form signed
- Pure intraventricular haemorrhages
- "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct
- Pre-admission modified Rankin score of 4 or 5
- Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
- Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)
- Adults who are deprived of their liberty by judicial or administrative decision
- Referral from other hospitals
- Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear...
- No consent form
The study team makes the final eligibility decision.
Where it's taking place
- Lille, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.